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sant medications are preferred to
benzodiazepines as a ﬁrst-line of
treatment for anxiety disorders in
the elderly.6 Psychotherapy, par-
ticularly cognitive behavior ther-
apy, is often effective in these disor-
ders as well.6
We reviewed symptoms of three
cases in which onset of anxiety
symptoms developed after age 60
as a result of having a medical pro-
cedure. They were highly function-
ing individuals and anxiety symp-
toms led to impairment of their
social and occupational life. They
were all successfully treated with
selective serotonin reuptake inhibi-
tor medications without any side ef-
fects and achieved the overall level
of functioning.
The ﬁrst case was a 61-year-old
male who worked in graphic art.
He developed severe neck pains
and a magnetic resonance imaging
scan (MRI) of cervical spines was
recommended. After having the
MRI, he developed recurrent unex-
pected panic attacks and anxiety
about being in a closed place. Com-
muting to work caused marked dis-
tress and he subsequently avoided
traveling in a bus, train, or car, and
his daily activities were restricted.
He initially refused to consider any
medications that might limit his
creativity. He agreed to a trial of
sertraline, 50 mg/day, which was
increased gradually to 100 mg. He
noted signiﬁcant improvement in
intensity and frequency of his panic
attacks and regained the ability to
use the public transportation with-
out any fear.
The second case involved a 61-
year-old female who was a medical
technician.
She suffered gastrointestinal re-
ﬂux disease and underwent diag-
nostic upper endoscopy. Since then,
she had been feeling anxious, and
had poor concentration, frequent
unpredicted panic attacks, and
anxiety about being in a crowd. She
could not resume her work and
preferred to stay home to avoid sit-
uations that might provoke her
anxiety. She was prescribed sertra-
line and was maintained on 150
mg/day. She reported lower anxi-
ety level, became comfortable in
public, and decided to look for a
part-time job.
The third case was a 75-year-old
male. He was a retired photogra-
pher and developed minor neuro-
logical deﬁcits. Computed tomogra-
phy scan (CT) of the head was
conducted. After the image study,
he started to have periods of in-
tense fear and excessive worry cued
by his presence in places from
which escape might be difﬁcult. He
isolated himself at home, stopped
going to church services and the se-
nior citizen center, and suffered de-
pression. He showed signiﬁcant
symptom response on paroxetine,
40 mg/day.
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To the Editor: Aripiprazole is the
ﬁrst partial agonist dopaminergic
D2 with clear antipsychotic effect.
Many schizophrenic patients will
develop comorbid substance abuse.
Cannabis consumption may worsen
psychotic symptoms of schizo-
phrenic patients.1 We describe the
case of a schizophrenic patient
whose use of cannabis and related
problems disappeared after treat-
ment with aripiprazole.
Mr. A, a 33-year-old Caucasian
patient with schizophrenia, has
since his mid-20s been treated with
olanzapine, 20 mg/day, and escital-
opram, 10 mg/day. He did reason-
ably well with this regimen but was
apragmatic. He frequently used
cannabis every day (urine screen
for tetrahydrocannabinol [THC]
was positive). He was moderately
obese (BMI: 28) but had no other
medical problems. He lived in a
community house, in which nurses
ensured that he was compliant with
treatment. His Brief Psychiatric Rat-
ing Scale (BPRS) score was 52. Be-
fore his mid-20s, the patient was
treated successively for different
classic antipsychotic conditions (i.e.,
haloperidol, bromperidol, and pi-
mozide) and he reported increased
cannabis abuse concomitant with
these regimens.
Aripiprazole, 15 mg/day, was
added to his treatment regimen. Af-
ter 1 week, the olanzapine dose was
decreased to 10 mg. One week later,
olanzapine was discontinued. After
5 weeks, escitalopram treatment
was discontinued because the pa-
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tient was euthymic. Three months
later, the patient signaled he felt
very good and did not need canna-
bis anymore. After 12 months of
treatment with aripiprazole the pa-
tient had not relapsed and did not
use cannabis at all (urine screen did
not reveal any THC). Moreover, his
BMI was 24 and BPRS score de-
creased to 40.
This case report highlights differ-
ent proposals about mechanism of
action and side effects.
First, the concurrence of the dimi-
nution of cannabis consumption
with the patient’s treatment with
aripiprazole suggests that aripipra-
zole contributed to the occurrence
of this diminution. Different mecha-
nisms may have played a part, such
as aripirazole’s partial agonism at
dopamine D2 receptors.2 A similar
observation was made with cocaine
dependence.3 Dopamine stimula-
tion in the nucleus accumbens has
been suggested to cause addictive
behavior and aripiprazole’s partial
dopamine agonist effect in this area
may reduce this behavior.4 In addi-
tion, aripiprazole has a number of
serotonergic actions that are not re-
lated to dopamine potentially mod-
ulating the response to THC.5,6
Other mechanisms may be involved
and Mr. A’s rapid cessation of can-
nabis use after starting aripiprazole
suggests the need to verify these
mechanisms systematically and to
plan controlled trials.
Second, several factors have to be
considered when regarding why
there may be a concomitant in-
crease in substance abuse with the
older antipsychotics. It was sug-
gested that a strong antagonist ef-
fect at the dopamine D2 receptors in
the nucleus accumbens was in-
volved in concomitant increase in
substance abuse with old antipsy-
chotics.7 Moreover, unrelated to do-
paminergic mechanisms, the use of
certain antipsychotics with substan-
tial side effects by schizophrenia
patients may actually contribute to
greater substance use in an effort to
self-medicate the side effects.8,9
Finally, there could be at least
two explanations for the weight
loss. The reduction of cannabis use
may have contributed to a reduc-
tion in eating,10 and the switch in
the antipsychotic to aripiprazole
may have been instrumental in
such a signiﬁcant weight reduction,
since aripiprazole is weight neutral
and olanzapine is known to facili-
tate weight gain in patients.
To our knowledge, this is the ﬁrst
reported case of aripirpazole’s effect
on cannabis use. More research is
needed to establish the beneﬁts of
aripiprazole in regard to cannabis.
Some dual diagnosis patients may
beneﬁt from aripiprazole, which
may reduce craving for and use of
cannabis.
Martin Desseilles, M.D.
Department of Psychiatry, Uni-
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To the Editor: Traumatic brain injury
(TBI) is frequently complicated by
alterations in temperament and
character that have adverse conse-
quences for day-to-day living, man-
ifesting as poor decision-making,
interpersonal problems, communi-
cation problems, and often overall
poor quality of life.1 Max et al.2
have reported extensively on the
correlates and predictors of person-
ality changes after traumatic brain
injury in children, but there is scant
mention in the literature on adults.
In this report, we describe the re-
sults of a preliminary study of the
clinical correlates of personality
change following traumatic brain
injury in adults.
Analysis
Data are from a retrospective chart
review of 54 subjects with closed
head injury enrolled in an outpa-
tient neuropsychiatry brain injury
clinic. Patients with depressed skull
fractures were excluded.
Every patient was evaluated and
followed by a clinic psychiatrist.
The assignment of personality
change due to a general medical
condition (TBI) diagnosis was based
